Alamar Biosciences has partnered with leading universities to launch a national-scale project profiling 21,000 plasma samples from 10,000 Alzheimer's and related dementia participants using its NULISAseq Neuro 220 panel. This initiative aims to accelerate biomarker discovery for neurodegenerative diseases by creating a publicly accessible dataset linked to extensive clinical and genetic data. The project supports AI-driven research and will host a national data challenge to foster new analytical methods. This effort could improve diagnosis, treatment, and understanding of Alzheimer's and related conditions.
During week 28 of 2026 (July 6-10), Sampo Oyj bought back a total of 35,203 of its own A-shares across multiple markets at a weighted average price of €9.32 per share. This buyback is part of a larger program authorized by the company's annual genera...
John Crane UK Limited has achieved Broad-Based Black Economic Empowerment (B-BBEE) Level One status in South Africa, the highest recognition under the country's transformation framework. This milestone enhances John Crane's position as a preferred su...
Chery Group showcased the FREELANDER 8 SUV at the Abu Dhabi Investment Forum, highlighting its Super Intelligent Valet Parking (SIVP) system. This smart parking technology allows remote parking and vehicle retrieval via a mobile app, designed to ease...
Chery Group has revealed the FREELANDER 8, a premium smart off-road SUV that blends British heritage design with modern technology. The exterior design emphasizes a balance of luxury, functionality, and durability, featuring a distinctive front inspi...
Gate has launched the second phase of its Pre-IPOs program, introducing a token linked to OpenAI, allowing users to participate using stablecoins USDT and GUSD. This product offers speculative exposure to OpenAI's anticipated public market value but ...
